Fortress Biotech (FBIO) Capital Expenditures Growth (3y) (2013 - 2024)
Powered by 
Analysis
Fortress Biotech (FBIO) Capital Expenditures Growth (3y) (2013 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 60.74% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 27.08% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -71.29% |
| Jun 30, 2024 | -4.53% |
| Dec 31, 2023 | -65.77% |
| Sep 30, 2023 | 26.03% |
| Jun 30, 2023 | -76.35% |
| Mar 31, 2023 | -67.82% |
| Dec 31, 2022 | -53.24% |
| Sep 30, 2022 | 25.15% |
| Jun 30, 2022 | -22.32% |
| Mar 31, 2022 | 64.56% |
| Dec 31, 2021 | 79.39% |
| Sep 30, 2021 | -39.96% |
| Jun 30, 2021 | -25.32% |
| Mar 31, 2021 | -10.69% |
| Dec 31, 2020 | 58.59% |
| Sep 30, 2020 | -43.52% |
| Jun 30, 2020 | 84.34% |
| Mar 31, 2020 | 27.42% |
| Dec 31, 2019 | 13.17% |
| Sep 30, 2019 | -29.97% |